Publications by authors named "C Abdeddaim"

Claim this Profile
H
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.
D M Filippini, B Cabarrou, C Dupain, M Halladjian, E Coquan, C Abdeddaim

ESMO Open· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real-World Study.
Alizée Simon, Cyril Abdeddaim, DucTrung Nguyen, Patrice Gallet, Didier Peiffert

Head Neck· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study.
Aurore Carrot, Pauline Corbaux, Olivier Colomban, Coriolan Lebreton, Laurence Gladieff, Cyril Abdeddaim

CPT Pharmacometrics Syst Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy.
Olivia Le Saux, Renaud Sabatier, Isabelle Treilleux, Léa-Isabelle Renaud, Pierre-Emmanuel Brachet, Cyril Abdeddaim

Ther Adv Med Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
R Galot, C Le Tourneau, L Licitra, J Guigay, A Kong, C Abdeddaim

ESMO Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis